262P Niraparib plus aromatase inhibitors (AI) for germinal mutated BRCA1/2 (gBRCAm) or homologous recombination-deficient (HRd), hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): LUZERN interim analysis
| Autor: | I. Pimentel, L. Lema Roso, M. Ramos Vazquez, J.Á. García Saenz, P. Palacios-Ozores, J. De la Haba Rodriguez, S. Blanch, A. Prat, J.E. Ales Martínez, E. Alba Conejo, J. Balmaña, J.M. Perez Garcia, M. Sampayo-Cordero, A. Malfettone, J. Cortés, A. Llombart Cussac |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Annals of Oncology. 33:S657 |
| ISSN: | 0923-7534 |
| DOI: | 10.1016/j.annonc.2022.07.301 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|